(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 27.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Cormedix's revenue in 2026 is $214,303,672.On average, 9 Wall Street analysts forecast CRMD's revenue for 2026 to be $28,562,604,593, with the lowest CRMD revenue forecast at $23,580,773,278, and the highest CRMD revenue forecast at $41,612,434,117. On average, 7 Wall Street analysts forecast CRMD's revenue for 2027 to be $25,446,497,864, with the lowest CRMD revenue forecast at $21,302,981,987, and the highest CRMD revenue forecast at $36,334,355,992.
In 2028, CRMD is forecast to generate $37,932,985,715 in revenue, with the lowest revenue forecast at $24,460,846,911 and the highest revenue forecast at $46,849,541,938.